German auto supplier Continental to cut 3,000 more jobs
German auto supplier Continental said Tuesday it will cut a further 3,000 jobs by the end of 2026, the latest sign of weakness for the country's auto sector.
The job reductions will be in research and development, it said, adding that less than half of the cuts will be in Germany.
Continental said the cuts would "to a large extent" take place via natural turnover, such as from retirement.
"We are continuously improving our competitive strengths in the interest of our sustainable market success," said Philipp von Hirschheydt, head of the automotive division at Continental.
Continental had already announced plans last February to cut 7,150 jobs by 2025.
The firm employs about 200,000 people worldwide with about 31,000 of those in research and development.
It has also announced it will spin off its automotive components business.
The news comes amid testing times for the European car industry, which is struggling with fierce Chinese competition and the shift to electric vehicles.
Sports car maker Porsche announced 1,900 layoffs last week, citing weak demand for its electric cars, and Volkswagen last December reached an agreement with unions to cut 35,000 jobs across its German locations by 2030.
BMW and Stellantis, which owns brands such as Fiat and Jeep, warned investors last year that their performance for 2025 would fall short of expectations, citing weak demand in China.
vbw/sr/rl
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
This growth stock just crashed 35%! Time to buy it for my Stocks and Shares ISA?
One growth stock stuck out like a sore thumb when I opened my Stocks and Shares ISA watchlist yesterday (23 June). That was Hims & Hers Health (NYSE: HIMS), which was down almost 35%, registering it's worst-ever day. This is a share I've been watching for a while, but haven't bought yet. Even after yesterday's crash, it's still up 86% over 12 months. Could this crash be an opportune time for me to nip in and open a position? Hims & Hers is a vertically integrated pharmacy and telehealth platform focused on personalised wellness. It offers prescription and over-the-counter treatments for hair loss, mental health, skincare, sexual health, and more. In 2024, the firm's revenue soared 69% year on year to $1.5bn. However, this isn't a jam-tomorrow growth story, because both net income and free cash flow more than quadrupled in Q1 of this year. Subscribers grew 38% to 2.4m. Driving some of this eye-catching growth has been compounded GLP-1 weight-loss drugs, which the firm began selling on its platform in 2024. In May, it announced a partnership with pharmaceutical giant Novo Nordisk to sell its blockbuster Wegovy treatment. Since that announcement, Hims & Hers stock has been rocketing. Until yesterday that is, when Novo terminated the collaboration. In a statement, the firm pulled no punches, accusing Hims of 'illegal mass compounding and deceptive marketing'. It used the words 'knock-off drugs' a number of times in relation to 'personalised' doses of semaglutide that Hims continues to sell. Semaglutide is the active ingredient in Wegovy. More seriously, Novo alleges that potentially unsafe active ingredients are being sourced from foreign suppliers in China, thereby putting patients at risk. Essentially then, there are three allegations here: The continued selling of copycat versions of Wegovy, which Novo says violates regulations. Deceptive marketing of these as 'personalised' treatments. Semaglutide sourced from unapproved Chinese suppliers. In response, Hims' CEO Andrew Dudum wrote on X: 'We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice.' Dudum said Novo's management is 'misleading the public', and that the platform will continue offering access to different weight-loss treatments, including semaglutide. What to make of all this? Well, there could obviously be regulatory compliance risk here. Lawsuits appear inevitable, and there's likely at least some brand damage. Meanwhile, Novo will keep selling Wegovy with two of Hims' rivals, namely Ro and LifeMD. So the firm could lose share in the booming weight-loss space, which isn't ideal. However, there's more to the platform than just Wegovy. It was already growing strongly before GLP-1s, and its opportunity to aggregate demand in some very large health categories appears undimmed to me. It's also expanding into Europe via a recent acquisition. Hims' disruptive direct-to-consumer platform aims to be cheaper and more personalised than the traditional healthcare model. Therefore, I think shareholders should expect further industry resistance, like Uber got from taxi firms. I'd like management to reassure investors about the supply chain accusations. Ideally, this will happen when the firm reports Q2 earnings in August, if not before. But if the stock keeps falling in the coming days, I will open a starter position. The post This growth stock just crashed 35%! Time to buy it for my Stocks and Shares ISA? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Ben McPoland has positions in Novo Nordisk and Uber Technologies. The Motley Fool UK has recommended Novo Nordisk and Uber Technologies. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business of Fashion
40 minutes ago
- Business of Fashion
Target Explores Factory-Direct Shipping Model Used by Temu
Target Corp. is testing the delivery of products directly to customers' homes from factories, said people familiar with the matter, an effort by the big-box retailer to launch a service similar to the Chinese e-commerce platforms Temu and Shein. The company is seeking to broaden its range of low-cost offerings through the initiative, said the people, who asked not to be named because the test hasn't been announced. Products would primarily include apparel, household goods and other non-food items, according to the people, who added the effort is in the early stages. A Target spokeswoman said the company is constantly testing new ways to deliver products and services. 'In all cases, we uphold the high quality, responsible sourcing and sustainability standards that Target is known for and that consumers expect from us,' she said. ADVERTISEMENT The Minneapolis-based retailer has struggled to revive sales growth in recent years and is looking for new avenues following choppy store traffic, soft demand and inventory missteps. Target shares are down 28 percent so far this year, while the S&P 500 Index has risen 3.6 percent, raising pressure on management to improve results. Most online orders from Target and other US retailers get sent to warehouses before going to consumers via truck delivery. By shipping directly from production sites, Target can offer lower prices and potentially increase market share among discounters. The X factor remains the US government's move to close the so-called de minimis exemption, which for years allowed Shein and Temu to capture market share by shipping orders of less than $800 to US customers duty free. The change has eroded performance at both companies, and could also impact direct-shipping efforts of Target and other retailers. After years of price increases across the economy, shoppers are spending less on toys, clothes and other discretionary items — Target's core categories. Tariffs are creating new challenges, as are boycotts after the company pulled back on diversity initiatives earlier this year. Target slashed its full-year sales forecast in May after missing Wall Street expectations for its last quarter. Target executives acknowledged then that they are not hitting the mark. Major holidays and limited-time design collaborations are bringing shoppers into stores, but the company isn't seeing that momentum every day, executives said. To counter this, the retailer is sharpening its focus on low prices and new products. In recent months, Target has said it's speeding up product development. Target's competition includes Temu, a unit of PDD Holdings Inc., Shein, Walmart Inc. and Inc., which started a low-cost online storefront called Haul that sells most items for under $20. By Jaewon Kang ADVERTISEMENT Learn more: Op-Ed | Target's DEI Flip-Flop Came at a Price Early data indicates Target and Walmart's store traffic has declined since their DEI exit, while Costco's has grown, signalling that we may be entering a new era of consumer boycotts.
Boston Globe
42 minutes ago
- Boston Globe
Celtics trade Kristaps Porzingis to Hawks in a three-way deal
More importantly, Boston will slide under the second apron after shedding Porzingis's $30.8 million salary, easing what would have become significant roster building restrictions. Advertisement With Jayson Tatum likely to miss all of next season because of an Achilles' injury he suffered last month, the Celtics will now open next season without at least three starters from their championship team two years ago. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Boston made its first significant move Monday night, when it agreed to trade Holiday to the Portland Trail Blazers in exchange for 26-year-old shooting guard Anfernee Simons and a pair of future second-round picks, according to league sources. Simons will make $27.7 million next season in the final year of a four-year, $100 million contract. Holiday, 35, inked a four-year, $135 million extension with the Celtics in April 2024 and will make $32.4 million next season. They also freed up long-term money, with Simons on an expiring deal and Holiday under contract for three more seasons. Advertisement A league source stressed late Monday night that the Celtics acquired Simons because they believe he can bolster the roster, but the source added that the team will 'remain engaged on all fronts' in the coming days and weeks. The Porzingis deal certainly reduces the chances that Boston will trade Simons, but it is still possible. On Tuesday, Porzingis shared a brief health update on Instagram. He thanked supporters and added, 'I've been feeling excellent all offseason and looking forward to a healthy and strong European championship tournament with [the Latvian national team].' Porzingis's expiring contract and his ability to help a team looking to make a title push were likely to make him an attractive option to potential suitors. Adam Himmelsbach can be reached at
